Ceritinib treatment slowed tumor growth (Fig. 3d) and improved survival (Fig. 3e) in mice injected with RDAA and ALK-rearranged (EML4-ALK) H1299 cells compared with control mice. This evidence concerns the gene ALK and neoplasm.